
Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Clears Ethics Review For Phase II Mpox Trial In DRC
(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC) announced approval from the Democratic Republic of Congo's National Ethics Committee for Health for its planned Phase II clinical trial of NV-387, a broad-spectrum antiviral …